Thalidomide and dexamethasone for newly diagnosed multiple myeloma: Is this really the standard of care?

被引：2

作者：

Nabhan, Chadi ^{[1
]}

Bitran, Jacob D. ^{[1
]}

机构：

[1] Lutheran Gen Hosp, Inst Canc, Park Ridge, IL 60068 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期

关键词：

D O I：

10.1200/JCO.2006.06.3115

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：2967 / 2968

页数：2

共 50 条

[21] Induction Treatment With Cyclophosphamide, Thalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: A Phase II Study
Yang, Deok-Hwan
Kim, Yeo-Kyeoung
Sohn, Sang-Kyun
Chung, Joo-Seop
Joo, Young-Don
Lee, Jae-Hoon
Lee, Jung-Lim
Ahn, Jae-Sook
Moon, Joon-Ho
Shin, Ho-Jin
Choi, Young-Jin
Lee, Won-Sik
Kim, Hyeoung-Joon
Lee, Je-Jung
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (01): : 62 - 67
[22] Efficacy and safety of thalidomide and dexamethasone combination with or without cyclophosphamide in patients with newly diagnosed multiple myeloma
Kim, Y.-K.
Lee, J. J.
Sohn, S. K.
Shin, H. J.
Lee, S. R.
Shim, H. J.
Ahn, J. S.
Kim, D. H.
Yang, D. H.
Cho, S. H.
Chung, I. J.
Kim, H. J.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 411 - 412
[23] Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma in Chinese patients
Cai, Zhen
Zheng, Weiyan
Wei, Guoqing
Ye, Xiujin
He, Jingsong
Li, Li
Wu, Wenjun
Lin, Maofang
BLOOD, 2007, 110 (11) : 281B - 281B
[24] Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: A Chinese experience
Zheng, Weiyan
Wei, Guoqing
Ye, Xiujin
He, Jingsong
Li, Li
Wu, Wenjun
Shi, Jimin
Zhang, Jie
Huang, Weijia
Xie, Wanzhuo
Luo, Yi
Xue, Xingkui
Lin, Maofang
Huang, He
Cai, Zhen
LEUKEMIA RESEARCH, 2009, 33 (12) : 1615 - 1618
[25] VTD (velcade, thalidomide, dexamethasone) as primary therapy for newly-diagnosed multiple myeloma.
Alexaman, R
Wang, LM
Weber, DM
Delasalle, KB
BLOOD, 2004, 104 (11) : 64A - 64A
[26] Cyclophosphamide, thalidomide and dexamethasone (CTD) as initial therapy for newly diagnosed multiple myeloma patients.
Chavez, Jule Franve Vasquez
Mendoza, Rossana Esther Ruiz
Llerena, Karina Mayra Aliaga
Valencia, Fernando
Enriquez, Daniel
Palacios, Victor
Casanova, Luis
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[27] Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients
Gay, Francesca
Hayman, Suzanne R.
Lacy, Martha Q.
Buadi, Francis
Gertz, Morie A.
Kumar, Shaji
Dispenzieri, Angela
Mikhael, Joseph R.
Bergsagel, P. Leif
Dingli, David
Reeder, Craig B.
Lust, John A.
Russell, Stephen J.
Roy, Vivek
Zeldenrust, Steven R.
Witzig, Thomas E.
Fonseca, Rafael
Kyle, Robert A.
Greipp, Philip R.
Stewart, A. Keith
Rajkumar, S. Vincent
BLOOD, 2010, 115 (07) : 1343 - 1350
[28] Thromboprophylaxis with aspirin for newly diagnosed multiple myeloma treated with thalidomide plus dexamethasone: A preliminary report.
Jimenez, Victor H.
Dominguez, Virginia
Reynoso, Eduardo
Lopez, Indira
BLOOD, 2006, 108 (11) : 362B - 362B
[29] Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma
Sonneveld, Pieter
Asselbergs, Emilie
Zweegman, Sonja
van der Holt, Bronno
Kersten, Marie Jose
Vellenga, Edo
van Marwijk-Kooy, Marinus
Broyl, Annemiek
de Weerdt, Okke
Lonergan, Sarah
Palumbo, Antonio
Lokhorstl, Henk
BLOOD, 2015, 125 (03) : 449 - 456
[30] Bortezomib, dexamethasone plus thalidomide for treatment of newly diagnosed multiple myeloma patients with or without renal impairment
Guangzhong Yang
Wenming Chen
Yin Wu
Chinese Journal of Cancer Research, 2013, 25 (02) : 155 - 160

← 1 2 3 4 5 →